Abel Hall LLC Acquires Shares of 10,071 Century Therapeutics, Inc. (NASDAQ:IPSC)

Abel Hall LLC acquired a new stake in Century Therapeutics, Inc. (NASDAQ:IPSC) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 10,071 shares of the company’s stock, valued at approximately $33,000.

Separately, Avidity Partners Management LP increased its stake in shares of Century Therapeutics by 23.4% in the 4th quarter. Avidity Partners Management LP now owns 1,355,000 shares of the company’s stock valued at $4,499,000 after buying an additional 256,500 shares during the period. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on IPSC shares. Piper Sandler reissued an “overweight” rating and issued a $9.00 target price (down from $10.00) on shares of Century Therapeutics in a research note on Friday, April 12th. Canaccord Genuity Group lifted their target price on Century Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Century Therapeutics in a research note on Tuesday, June 4th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Century Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.20.

Century Therapeutics Stock Performance

Shares of Century Therapeutics stock traded down $0.13 during trading on Friday, reaching $3.13. The stock had a trading volume of 110,931 shares, compared to its average volume of 121,281. The stock has a fifty day moving average price of $3.18 and a two-hundred day moving average price of $3.53. Century Therapeutics, Inc. has a 52 week low of $1.28 and a 52 week high of $5.51.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.05. The company had revenue of $0.86 million for the quarter, compared to analyst estimates of $0.30 million. Century Therapeutics had a negative return on equity of 59.74% and a negative net margin of 9,742.41%. Equities analysts predict that Century Therapeutics, Inc. will post -1.94 earnings per share for the current fiscal year.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.